Tissue Regenix Group PLC Further Medicare Coverage Approval for DermaPure (7007M)

TIDMTRX

RNS Number : 7007M

Tissue Regenix Group PLC

11 May 2015

Tissue Regenix Group plc

Further Medicare Coverage Approval for DermaPure(R)

YORK, 11 May 2015 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, today announces it has secured approval from CGS Medicare for coverage of DermaPure(R) reimbursement. CGS covers the states of Ohio and Kentucky and adds a further 1.9m Medicare beneficiaries who can now receive the outstanding clinical benefits of the product.

Tissue Regenix launched DermaPure(R) in 2014 and has since made significant progress in not only demonstrating the clinical benefits but also securing reimbursement for it. In March we announced that DermaPure(R) had been approved for reimbursement from the Novitas administrator and the combination of this and CGS means that DermaPure(R) is now available to 10.8 million Medicare beneficiaries across 14 states.

Today's announcement is evidence of the growing momentum behind the product but also is further validation of TR's ability to deploy its technology commercially.

Antony Odell, CEO of Tissue Regenix commented:

"We welcome CGS' decision to provide coverage in what is an important additional step in achieving our strategic objective of full commercialisation of DermaPure(R) in the United States. We continue to work hard to raise awareness of the product based on the strong clinical outcomes for patients and we are delighted to get CGS coverage so soon after Novitas in March."

ENDS

For Further Information

Tissue Regenix Group Plc: +44 19 0443 5176

Antony Odell

Ian Jefferson

Jefferies International Ltd: +44 20 7029 8000

Simon Hardy

Harry Nicholas

   Tulchan Communications:                                                           +44 207 353 4200

Tom Buchanan

Victoria Huxster

Matt Low

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL(R) technology platform.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUGURAAUPAGAR

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024